CN111544522A - 一种治疗消化道肿瘤引发贫血的中药组合物及其制备方法 - Google Patents
一种治疗消化道肿瘤引发贫血的中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN111544522A CN111544522A CN202010387030.8A CN202010387030A CN111544522A CN 111544522 A CN111544522 A CN 111544522A CN 202010387030 A CN202010387030 A CN 202010387030A CN 111544522 A CN111544522 A CN 111544522A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- medicine composition
- chinese medicine
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 239000003814 drug Substances 0.000 title claims abstract description 55
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 44
- 208000007502 anemia Diseases 0.000 title claims abstract description 34
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 51
- 108010010803 Gelatin Proteins 0.000 claims abstract description 38
- 229920000159 gelatin Polymers 0.000 claims abstract description 38
- 239000008273 gelatin Substances 0.000 claims abstract description 38
- 235000019322 gelatine Nutrition 0.000 claims abstract description 38
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 38
- 241001313857 Bletilla striata Species 0.000 claims abstract description 37
- 239000002674 ointment Substances 0.000 claims abstract description 16
- 241000405414 Rehmannia Species 0.000 claims abstract description 15
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 13
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 13
- 235000008434 ginseng Nutrition 0.000 claims abstract description 13
- 241000219068 Actinidia Species 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract 4
- 239000000706 filtrate Substances 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- 108010052008 colla corii asini Proteins 0.000 claims description 28
- 239000000843 powder Substances 0.000 claims description 28
- 239000011812 mixed powder Substances 0.000 claims description 23
- 238000002844 melting Methods 0.000 claims description 16
- 230000008018 melting Effects 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 15
- 239000008187 granular material Substances 0.000 claims description 14
- 235000006533 astragalus Nutrition 0.000 claims description 10
- 238000004140 cleaning Methods 0.000 claims description 10
- 238000010025 steaming Methods 0.000 claims description 10
- 229940056582 human hair preparation Drugs 0.000 claims description 9
- 238000010298 pulverizing process Methods 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 8
- 241001061264 Astragalus Species 0.000 claims description 7
- 210000004233 talus Anatomy 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 5
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims description 3
- 244000236658 Paeonia lactiflora Species 0.000 claims description 3
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 241000510667 Conioselinum Species 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 244000061520 Angelica archangelica Species 0.000 claims 1
- 244000131316 Panax pseudoginseng Species 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 52
- 210000004369 blood Anatomy 0.000 abstract description 50
- 230000000740 bleeding effect Effects 0.000 abstract description 31
- 241000208340 Araliaceae Species 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 208000025865 Ulcer Diseases 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 8
- 241000213006 Angelica dahurica Species 0.000 abstract description 7
- 241000212322 Levisticum officinale Species 0.000 abstract description 7
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract description 7
- 239000001645 levisticum officinale Substances 0.000 abstract description 7
- 230000035876 healing Effects 0.000 abstract description 5
- 238000005469 granulation Methods 0.000 abstract description 4
- 230000003179 granulation Effects 0.000 abstract description 4
- 231100000397 ulcer Toxicity 0.000 abstract description 4
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 210000004204 blood vessel Anatomy 0.000 abstract description 2
- 239000009636 Huang Qi Substances 0.000 abstract 2
- 244000170916 Paeonia officinalis Species 0.000 abstract 2
- 229940100615 topical ointment Drugs 0.000 abstract 1
- 208000032843 Hemorrhage Diseases 0.000 description 31
- 230000000694 effects Effects 0.000 description 27
- 230000001737 promoting effect Effects 0.000 description 16
- 238000005534 hematocrit Methods 0.000 description 14
- 230000007812 deficiency Effects 0.000 description 12
- 239000003921 oil Substances 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 102000001554 Hemoglobins Human genes 0.000 description 8
- 108010054147 Hemoglobins Proteins 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 8
- 235000013601 eggs Nutrition 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 206010027514 Metrorrhagia Diseases 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 230000017423 tissue regeneration Effects 0.000 description 6
- 241001106477 Paeoniaceae Species 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 239000000341 volatile oil Substances 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000036269 ulceration Effects 0.000 description 4
- 241000125175 Angelica Species 0.000 description 3
- 241000045403 Astragalus propinquus Species 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 3
- 208000034507 Haematemesis Diseases 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 201000004101 esophageal cancer Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 208000033809 Suppuration Diseases 0.000 description 2
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 229940096998 ursolic acid Drugs 0.000 description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 244000298715 Actinidia chinensis Species 0.000 description 1
- 235000009434 Actinidia chinensis Nutrition 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241001313855 Bletilla Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- QIIDATRCGITYRZ-UHFFFAOYSA-N Catalpol Natural products OCC1OC(OC2OC=CC3C(O)C(=C(CO)C23)O)C(O)C(O)C1O QIIDATRCGITYRZ-UHFFFAOYSA-N 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000007126 Codonopsis pilosula Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- 206010013833 Duodenal polyp Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010017817 Gastric polyps Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010018045 Gastroptosis Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- DEQFJPVWHOMNOG-UHFFFAOYSA-N Leonurin Natural products COc1cc(cc(OC)c1O)C(=O)N(CCCCO)C(=N)N DEQFJPVWHOMNOG-UHFFFAOYSA-N 0.000 description 1
- WNGSUWLDMZFYNZ-UHFFFAOYSA-N Leonurine Natural products COC1=CC(C(=O)OCCCCN=C(N)N)=CC(OC)=C1O WNGSUWLDMZFYNZ-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000112528 Ligusticum striatum Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010036176 Melitten Proteins 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 206010051935 Oesophageal polyp Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010061577 Ulcer haemorrhage Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- RJWJHRPNHPHBRN-FKVJWERZSA-N aucubin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(CO)=C[C@@H](O)[C@@H]2C=CO1 RJWJHRPNHPHBRN-FKVJWERZSA-N 0.000 description 1
- UTDFQMAXCUGNJR-UHFFFAOYSA-N aucubin Natural products OCC1OC(Oc2ccoc2C3C(O)CCC3O)C(O)C(O)C1O UTDFQMAXCUGNJR-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- LHDWRKICQLTVDL-PZYDOOQISA-N catalpol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2[C@@]3(CO)O[C@H]3[C@@H](O)[C@@H]2C=CO1 LHDWRKICQLTVDL-PZYDOOQISA-N 0.000 description 1
- UXSACQOOWZMGSE-UHFFFAOYSA-N catalposide Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(OC(=O)C=3C=CC(O)=CC=3)C2C=CO1 UXSACQOOWZMGSE-UHFFFAOYSA-N 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 208000018997 giddiness Diseases 0.000 description 1
- 229940107131 ginseng root Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- LHDWRKICQLTVDL-UHFFFAOYSA-N methyl iridoid glycoside Natural products OC1C(O)C(O)C(CO)OC1OC1C2C3(CO)OC3C(O)C2C=CO1 LHDWRKICQLTVDL-UHFFFAOYSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- -1 qi is commander Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000008747 shengyu Substances 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Zoology (AREA)
Abstract
本发明涉及一种治疗消化道肿瘤引发贫血的中药组合物及其制备方法,所述中药组合物,通过采用中药熟地、白芍、川芎、人参、当归、黄芪、藤梨根、阿胶、白芨和血余炭为原料,其中熟地、白芍是阴柔补血之品,当归、川芎是血中气药,加入人参、黄芪固摄血液,加入白芨、血余炭敛疮止血,阿胶粘附止血生血,加强摄血止血养血功能,加入藤梨根抗肿瘤、抗溃疡、促进创伤愈合。应用全身内服法和局部外科油膏外敷法。本发明所述中药组合物能够一方两用、一方两服治疗消化道肿瘤引发的贫血;内服法益气补血、扶正固本,油膏外敷,粘附在肿瘤局部,粘附肿瘤血管,治疗肿瘤局部疮疡溃烂,敛疮生肌、摄血止血,专治出血、以治其标。
Description
技术领域
本发明属于中药技术领域,具体涉及一种治疗消化道肿瘤引发贫血的中药组合物及其制备方法。
背景技术
消化道肿瘤,主要包括像食管肿瘤、胃部肿瘤、小肠肿瘤、大肠肿瘤等等,结直肠肿瘤都是属于大肠肿瘤的一种。消化道肿瘤继发出血是比较常见的,上消化道肿瘤是引起上消化道出血的常见病因之一,约占所有上消化道出血病因的2%-3%。良性肿瘤中以食管、胃及十二指肠息肉或息肉病最常见,此外,平滑肌瘤、腺瘤或神经纤维瘤等也可引起上消化道出血。恶性肿瘤主要有食道癌、胃癌、直结肠癌等。临床疾病出血时,可能需要根据病情状况进行治疗,如继发消化道大出血时,常常需要进行肿瘤切除手术,如果少量出血或者渗血时,一般需要根据病情选择药物控制治疗,但是多数药物效果欠佳。
发明内容
为了解决现有技术存在的以上问题,本发明提供了一种治疗消化道肿瘤引发贫血的中药组合物及其制备方法。
本发明所采用的技术方案为:
一种治疗消化道肿瘤引发贫血的中药组合物,原料组分包括:阿胶5-30重量份、白芨9-12重量份、血余炭10-20重量份。
进一步,所述中药组合物的剂型为油膏剂。
所述治疗消化道肿瘤引发贫血的中药组合物油膏剂的制备方法具体如下:
按照所述重量份阿胶进行烊化,得到烊化阿胶;取所述重量份白芨洗净、干燥,之后和血余炭分别进行粉碎,得到白芨粉和血余炭粉;将所述烊化阿胶、白芨粉和血余炭粉混合均匀,得到混合物;向所述混合物中加入鸡蛋油并搅拌均匀,得到所述油膏剂。
进一步,将阿胶粉碎,加入为阿胶质量1-2倍的温水,放入蒸锅,隔水蒸之,直到融化,得到所述烊化阿胶。
进一步,所述白芨粉和血余炭粉的粒径为200目,所述鸡蛋油的加入量为所述混合物的3%-5%。
进一步,出血量较大者加用本方,阿胶烊化后呈胶东样,具有很好粘附作用,与止血药白芨、血余炭粉剂混合后强化粘附止血作用,鸡蛋油具有促进创面愈合作用。服药后继用粘性粳米汤送服,加强粘膜保护,达到覆盖创面,粘附出血点,快速止血之目的;适用于局部疮疡溃烂、敛疮生肌、摄血止血,专治出血、以治其标。
进一步,所述原料组分还包括:熟地15-20重量份、白芍10-15重量份、川芎8-10重量份、当归9-15重量份、人参10-20重量份、黄芪10-30重量份、藤梨根20-60重量份。
进一步,所述中药组合物的剂型为颗粒剂或胶囊剂。
所述治疗消化道肿瘤引发贫血的中药组合物颗粒剂的制备方法具体如下:
(1)按照所述重量份阿胶进行烊化,得到烊化阿胶;
(2)将剩余所述各原料依次进行清洗、干燥、粉碎、混合,得到原料混合粉,向所述原料混合粉中加水进行第一次煎煮,过滤后得到第一滤渣和第一滤液;向所述第一滤渣中加水进行第二次煎煮,过滤后得到第二滤渣和第二滤液;向所述第二滤渣中加水进行第三次煎煮,过滤后得到第三滤渣和第三滤液;将所述各原料第一滤液、第二滤液、第三滤液和步骤(1)中的烊化阿胶混合均匀,得到合并液;将所述合并液依次进行浓缩、干燥、粉碎,得到所述颗粒剂。
进一步,步骤(1)中,所述烊化为:将阿胶粉碎,加入为阿胶质量1-2倍的温水,放入蒸锅,隔水蒸之,直到融化,得到所述烊化阿胶。
进一步,步骤(2)中,所述原料混合粉的粒径为50-100目;所述三次加水的量均为所述原料混合粉质量的4-6倍,所述第一次煎煮的时间为80-100min,所述第二次煎煮的时间为50-70min,所述第三次煎煮的时间为30-50min。
进一步,内服改善癌症病人体质,益气补血、扶正固本;出血量不多直接服用颗粒剂或胶囊剂,出血量较大者可联合使用油膏剂快速止血。
为了便于理解本发明,下面对本发明中的原料及药效作进一步阐述。
当归,性温,味甘、辛。归心、肝、脾经。补血和血,调经止痛。治疗症瘕结聚、崩漏、痈疽疮窃、跌扑损伤。当归主要含蔗糖、多种氨基酸、挥发油以及正丁烯、内酯、烟酸、阿魏酸和半萜类化合物,还含有维生素A、维生素E、挥发油、精氨酸及多种矿物质。能补血,显著促进机体造血功能,升高红细胞、白细胞和血红蛋白含量;调血脂,抑制血小板凝聚,抗血栓,调节血脂;降血压、抗心肌缺血、心律失常,扩张血管,降低血压;增强免疫力、抗炎、保肝、抗辐射、抗氧化和清除自由基等。
白芍,味苦,性平。《别录》:“通顺血脉、缓中、散恶血、逐贼血”。功能主治:养血柔肝、缓中止痛、敛阴收汗。治胸腹胁肋疼痛、泻痢腹痛、自汗盗汗、阴虚发热、月经不调、崩漏、带下。成份:根含芍药甙、牡丹酚、芍药花甙,苯甲酸约1.07%、挥发油、脂肪油、树脂、鞣质、糖、淀粉、粘液质、蛋白质、β-谷甾醇和三萜类。
川芎,味辛,性温。入肝、胆经。功用主治:行气开郁、祛风燥湿、活血止痛。治产后瘀阻块痛、痈疽疮疡。主治经闭痛经、癥瘕腹痛、胸胁刺痛、跌扑肿痛;抗放射作用,川芎水溶性粗制剂对大鼠、小鼠及犬的放射线照射与氮芥损伤均有保护作用。
熟地,味甘,性微温。归肝、肾经。功能主治:滋阴补血,益精填髓。用于肝肾阴虚,腰膝酸软,骨蒸潮热,盗汗遗精,内热消渴,血虚萎黄,心悸怔忡,月经不调,崩漏下血,眩晕,耳鸣,须发早白。化学成分:熟地黄含较少量的环烯醚萜类成分,已分离得到:益母草甙、桃叶珊瑚甙、梓醇、地黄甙A、B、C、D,美利妥双甙,地黄素A、D,地黄氯化臭蚁醛甙等。补血:用水煎服熟地黄,可以促进贫血的人群的红细胞和血红蛋白的快速恢复,还能够加快多功能造血干细胞的增殖和分化。补肾益髓:熟地黄能够补精益髓以达到生血的目的,还可以缓解人体血虚所造成的一些疾病,是治疗血虚证很好的药物,熟地黄又是入肝肾两经的药物,所以具有补益肝肾、滋阴补血、益精填髓的功效。
人参,味甘、微苦、微温,归脾、肺、心、肾经。人参的功效是补气,固脱,生津,安神,益智,用于体虚欲脱,肢冷脉微,脾虚食少,肺虚喘咳,津伤口渴,内热消渴,久病虚羸,惊悸失眠,阳痿宫冷。主要成分:皂苷类,人参皂苷系人参皂苷元与糖类的结合物,挥发油类,氨基酸和肽类,其他成分维生素类包括B1、B2、C等多种维生素;微量元素已检出20多种,其中人体必需的有铁、铜、锌、锰、钴、硒、镍等;人体必需的常量元素有钾、钠、钙、镁。
黄芪,味甘,微温。归脾、肺经。是常用的补益气血之佳品,补脾益气,益气升阳。用于气虚下陷之症。可治疗胃下垂、以及气虚血脱的崩漏等症。托疮排脓用于气虚痈疽久不溃破,或溃后久不愈合。取本品补气健脾,能促进脓疱的早溃和肌肉的新生,有排脓生肌作用。中医认为补气有助生血,所以在治疗各种血虚症时加入补气的黄芪、党参可以加强补血作用,对癌症放化疗期间使用黄芪可增强抗癌药的效果,减轻放化疗的不良反应,保护正常细胞,防止骨髓抑制。
阿胶,性平,味甘,补血、滋阴、润肺、止血。阿胶块能补血滋阴,常常配合当归、熟地、白芍、白术等用于血虚症。常治疗各种贫血,现代研究中,这个药可以促进红细胞与血红蛋白的增加。治疗缺铁性贫血,再生障碍性贫血,血小板减少,白细胞减少等症效果明显。通常认为:阿胶是通过滋阴润燥而止血,本方通过改变剂型,利用膏剂的粘附性而快速止血,这是本方的创新之处。
白芨,味苦、甘、涩,微寒。归肺、肝、胃经。功效:收敛止血,消肿生肌。主治:内外伤出血、用于咳血吐血,外伤出血,疮疡肿毒,肺结核咳血,溃疡病出血。白芨具有较好的收敛止血,消肿生肌功效。随着现代药理学的研究不断深入,发现其对肿瘤细胞有明显抑制作用。临床用于内外出血诸证及痈肿等。白及含大量黏胶质多糖、多酚类、菲类、芪类、挥发油等成分,具有清热利湿、消肿生肌、收敛止血的作用。
血余炭,味苦、微温。主治吐血、衄血、血痢、血淋、妇女崩漏等证。熬膏外敷止血生肌。头发含胱氨酸(Cystine)是角蛋白的一种。此外,含有脂类。血余炭主要为碳素。功能止血散瘀:用于各种出血性疾病,尤以血淋、崩漏和吐血之证多用,常与其他止血药同用,对外伤出血或久溃不敛者,可研末撒创面上,或熬膏外敷。生肌敛疮:可用本品与当归等药用香油炸枯入黄蜡为膏外敷。外用止血兼能生肌,治久溃不敛。
鸡蛋油是从鸡蛋的蛋黄中煎取的油,又称鸡子鱼、凤凰油等。蛋黄油是治疗轻度烫伤的良药,这是因为蛋黄油含有丰富的维生素A、D和卵磷脂等,这些物质对人体皮肤的再生和代谢有着重要作用,具有生肌长皮,消肿止痛,敛疮收口的作用。
藤梨根,味酸、苦涩,性凉。归肺、肝、大肠经。功能:清热利湿、疏淤通络、祛风除痹、解毒利尿、止血消肿。主治:消化道肿瘤、消化道癌肿、痈疡疮疖、外伤出血。藤梨根最常用于消化系统恶性肿瘤的治疗,如胃癌,肠癌,食道癌等。尤其对于肠胃道方面的癌症应用更多,具有增强细胞免疫和抑制体液免疫的作用,其抗肿瘤作用可能部分与其促进淋巴细胞转化和增强NK细胞活性有关。营养价值:藤梨根含熊果酸、齐墩果酸、琥珀酸、胡萝卜甙以及精氨酸、赖氨酸、亮氨酸、丙氨酸、天门冬氨酸等并富含Fe、Cu、Mn、Se等元素。藤梨根其中成分齐墩果酸类和乌苏酸类对人体结肠癌细胞和人体肝癌细胞有一定的抑制活性,其抑制活性的强弱与成分的极性的大小相关。提取物具有一定的抗肿瘤作用,其活性成分主要存在于极性较小的一部分。具有良好的抗溃疡,促进创伤愈合,胃肠黏膜保护作用及抗炎作用。
本发明所述中药组合物的有益效果:
本发明所述的治疗消化道肿瘤引发贫血的中药组合物通过采用中药熟地、白芍、川芎、人参、当归、黄芪、藤梨根、阿胶、白芨和血余炭为原料,其中熟地、白芍是阴柔补血之品,当归、川芎是血中气药,加入人参、黄芪固摄血液,加入白芨、血余炭敛疮止血,阿胶粘附止血生血,加强摄血止血养血功能,加入藤梨根抗肿瘤、抗溃疡、促进创伤愈合,上述诸药协同发挥药效,共同起到益气补血、扶正固本的功效,共同起到治疗消化道肿瘤引起的贫血的作用。
本发明所述中药组合物应用传统名方圣愈汤进行加减组方得到,具体取自清朝御医吴谦主编的《医宗金鉴》,主要具有益气、补血、摄血功能,由四物汤合人参、黄芪组成,四物汤中熟地、白芍是阴柔补血之品,是血中的血药,当归、川芎是血中气药,气为血帅,血为气母,气行则血行,气滞则血瘀;四物汤被誉为妇科第一药方,补血而不滞血,活血而不伤血,在此基础上加入补气药人参、黄芪固摄血液,加入白芨、血余炭敛疮止血,阿胶粘附止血生血,加强摄血止血养血功能,对消化道肿瘤因出血和化疗副作用引起的贫血有较好的治疗作用,藤梨根具有抗肿瘤作用,抗溃疡,促进创伤愈合,胃肠黏膜保护作用及抗炎作用。应用全身内服法和局部外科油膏外敷法,本发明所述中药组合物能够一方两用、一方两服治疗消化道肿瘤引发的贫血,内服法益气补血、扶正固本,油膏外敷法治疗肿瘤局部疮疡溃烂,敛疮生肌、摄血止血,专治出血、以治其标,对消化道肿瘤,特别是溃疡型消化道肿瘤有较好的治疗效果;出血量不多直接服用颗粒剂或胶囊剂,出血量较大者可联合使用油膏剂快速止血。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚,下面将对本发明的技术方案进行详细的描述。显然,所描述的实施病例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动的前提下所得到的所有其它实施方式,都属于本发明所保护的范围。
以下实施例中以1重量份代表1g。
实施例1
本实施例提供一种治疗消化道肿瘤引发贫血的中药组合物,由以下原料制备而成:阿胶5重量份、白芨9重量份、血余炭10重量份。
本实施例所述治疗消化道肿瘤引发贫血的中药组合物油膏剂的制备方法,包括如下步骤:
将阿胶粉碎,加入与阿胶质量相等的温水,放入蒸锅,隔水蒸之,直到融化,得到烊化阿胶;取所述重量份白芨洗净、干燥,之后和血余炭分别进行粉碎为粒径至200目,得到白芨粉和血余炭粉;将所述烊化阿胶、白芨粉和血余炭粉混合均匀,得到混合物;向所述混合物中加入为所述混合物质量3%的鸡蛋油并搅拌均匀,得到所述油膏剂。
实施例2
本实施例提供一种治疗消化道肿瘤引发贫血的中药组合物,由以下原料制备而成:阿胶30重量份、白芨12重量份、血余炭20重量份。
本实施例所述治疗消化道肿瘤引发贫血的中药组合物油膏剂的制备方法,包括如下步骤:
将阿胶粉碎,加入为阿胶质量2倍的温水,放入蒸锅,隔水蒸之,直到融化,得到烊化阿胶;取所述重量份白芨洗净、干燥,之后和血余炭分别进行粉碎为粒径至200目,得到白芨粉和血余炭粉;将所述烊化阿胶、白芨粉和血余炭粉混合均匀,得到混合物;向所述混合物中加入为所述混合物质量5%的鸡蛋油并搅拌均匀,得到所述油膏剂。
实施例3
本实施例提供一种治疗消化道肿瘤引发贫血的中药组合物,由以下原料制备而成:阿胶17.5重量份、白芨11重量份、血余炭15重量份。
本实施例所述治疗消化道肿瘤引发贫血的中药组合物油膏剂的制备方法,包括如下步骤:
将阿胶粉碎,加入为阿胶质量1.5倍的温水,放入蒸锅,隔水蒸之,直到融化,得到烊化阿胶;取所述重量份白芨洗净、干燥,之后和血余炭分别进行粉碎为粒径至200目,得到白芨粉和血余炭粉;将所述烊化阿胶、白芨粉和血余炭粉混合均匀,得到混合物;向所述混合物中加入为所述混合物质量4%的鸡蛋油并搅拌均匀,得到所述油膏剂。
实施例4
本实施例提供一种治疗消化道肿瘤引发贫血的中药组合物,由以下原料制备而成:
阿胶5重量份、白芨9重量份、血余炭10重量份、熟地15重量份、白芍10重量份、川芎8重量份、当归9重量份、人参10重量份、黄芪10重量份、藤梨根20重量份。
本实施例所述治疗消化道肿瘤引发贫血的中药组合物颗粒剂的制备方法,包括如下步骤:
(1)将阿胶粉碎,加入为与阿胶质量相等的温水,放入蒸锅,隔水蒸之,直到融化,得到烊化阿胶;
(2)将剩余所述各原料依次进行清洗、干燥,粉碎粒径至50目,混合,得到原料混合粉,向所述原料混合粉中加为所述原料混合粉质量4倍的水进行第一次煎煮80min,过滤后得到第一滤渣和第一滤液;向所述第一滤渣中加为所述原料混合粉质量4倍的水进行第二次煎煮50min,过滤后得到第二滤渣和第二滤液;向所述第二滤渣中加为所述原料混合粉质量4倍的水进行第三次煎煮30min,过滤后得到第三滤渣和第三滤液;将所述各原料第一滤液、第二滤液、第三滤液和步骤(1)中的烊化阿胶混合均匀,得到合并液;将所述合并液依次进行浓缩、干燥、粉碎,得到所述颗粒剂。
实施例5
本实施例提供一种治疗消化道肿瘤引发贫血的中药组合物,由以下原料制备而成:
阿胶30重量份、白芨12重量份、血余炭20重量份、熟地20重量份、白芍15重量份、川芎10重量份、当归15重量份、人参20重量份、黄芪30重量份、藤梨根60重量份。
本实施例所述治疗消化道肿瘤引发贫血的中药组合物颗粒剂的制备方法,包括如下步骤:
(1)将阿胶粉碎,加入为阿胶质量2倍的温水,放入蒸锅,隔水蒸之,直到融化,得到烊化阿胶;
(2)将剩余所述各原料依次进行清洗、干燥,粉碎粒径至100目,混合,得到原料混合粉,向所述原料混合粉中加为所述原料混合粉质量6倍的水进行第一次煎煮100min,过滤后得到第一滤渣和第一滤液;向所述第一滤渣中加为所述原料混合粉质量6倍的水进行第二次煎煮70min,过滤后得到第二滤渣和第二滤液;向所述第二滤渣中加为所述原料混合粉质量6倍的水进行第三次煎煮50min,过滤后得到第三滤渣和第三滤液;将所述各原料第一滤液、第二滤液、第三滤液和步骤(1)中的烊化阿胶混合均匀,得到合并液;将所述合并液依次进行浓缩、干燥、粉碎,得到所述颗粒剂。
实施例6
本实施例提供一种治疗消化道肿瘤引发贫血的中药组合物,由以下原料制备而成:
阿胶17.5重量份、白芨11重量份、血余炭15重量份、熟地18重量份、白芍13重量份、川芎9重量份、当归12重量份、人参15重量份、黄芪20重量份、藤梨根40重量份。
本实施例所述治疗消化道肿瘤引发贫血的中药组合物颗粒剂的制备方法,包括如下步骤:
(1)将阿胶粉碎,加入为阿胶质量1.5倍的温水,放入蒸锅,隔水蒸之,直到融化,得到烊化阿胶;
(2)将剩余所述各原料依次进行清洗、干燥,粉碎粒径至75目,混合,得到原料混合粉,向所述原料混合粉中加为所述原料混合粉质量5倍的水进行第一次煎煮90min,过滤后得到第一滤渣和第一滤液;向所述第一滤渣中加为所述原料混合粉质量5倍的水进行第二次煎煮60min,过滤后得到第二滤渣和第二滤液;向所述第二滤渣中加为所述原料混合粉质量5倍的水进行第三次煎煮40min,过滤后得到第三滤渣和第三滤液;将所述各原料第一滤液、第二滤液、第三滤液和步骤(1)中的烊化阿胶混合均匀,得到合并液;将所述合并液依次进行浓缩、干燥、粉碎,得到所述颗粒剂。
实验例
本发明实施例6所得中药组合物效果验证试验
1、试验方法:将承德市某三甲医院2018年1月至2019年1月收治的60例消化道肿瘤贫血患者随机分成观察组和对照组,每组各30例;60例肿瘤贫血患者中包括食道癌3例,胃癌19例,结肠癌4例,直肠癌4例;年龄最小的31岁,最大的86岁,平均年龄53.50±6.78岁,所有患者均经本院确诊为恶性肿瘤。患者入院后进行常规化验血常规,包括血红蛋白和血细胞容积,其中血红蛋白<105g/L,血细胞比容<40VOL/%列为本次实验对象,肝肾功能检查均正常。在抗肿瘤治疗的基础上,对照组给予补血药硫酸亚铁治疗,观察组给予同等量的本发明实施例6所得中药组合物,治疗贫血20天后比较两组患者的血红蛋白(Hb)和血细胞比容(HCT)变化。
2、评价指标及评判标准
观察两组患者治疗前后血红蛋白和血细胞比容变化情况及两组患者治疗有效率比较,并进行统计学处理,评价治疗效果。两组患者治疗后Hb>120g/L且未进行输血为有效;相反为无效。
3、评价方法
使用SPSS 13.0统计软件进行统计分析,两组数据资料用t检验和χ2检验进行统计分析,以P<0.05为差异有统计意义。
4、结果如表1-表5所示
表1-观察组患者治疗前后Hb和HCT比较
观察组患者治疗前后Hb和HCT比较,差异具有统计学意义(P<0.05)。
表2-对照组患者治疗前后Hb和HCT比较
对照组患者治疗前后Hb比较,Hb没升反降。治疗前后HCT比较,差异无统计学意义(P>0.05)。
表3-观察组和对照组患者治疗前的Hb和HCT比较
治疗前观察组和对照组患者的Hb和HCT比较,差异无统计学意义(P>0.05)。
治疗后观察组患者的Hb和HCT均高于对照组,差异具有统计学意义(P<0.05)。
表5-两组患者治疗有效率比较
组别 | 有效 | 无效 | 有效率(%) |
观察组 | 26 | 4 | 86 |
对照组 | 11 | 19 | 36 |
合计 | 37 | 23 | 62 |
注:x2=15.86x2>x2 0.05(1)P<0.05
两组患者治疗有效率比较,观察组患者治疗有效率明显高于对照组,差异具有统计学意义(P<0.05)。
观察组的血红蛋白(Hb)和血细胞比容(HCT)变化程度高于对照组,差异具有统计学意义(P<0.05),观察组患者治疗有效率明显高于对照组(P<0.05)。综上所述,本发明实施例6提供的治疗消化道肿瘤并发贫血的中药组合物,治疗效果明显优于单纯西药治疗效果,具有临床推广意义。
以上所述,仅为本发明的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,可轻易想到变化或替换,都应涵盖在本发明的保护范围之内。因此,本发明的保护范围应以所述权利要求的保护范围为准。
Claims (10)
1.一种治疗消化道肿瘤引发贫血的中药组合物,其特征在于,原料组分包括:阿胶5-30重量份、白芨9-12重量份、血余炭10-20重量份。
2.根据权利要求1所述的治疗消化道肿瘤引发贫血的中药组合物,其特征在于,所述原料组分还包括:熟地15-20重量份、白芍10-15重量份、川芎8-10重量份、当归9-15重量份、人参10-20重量份、黄芪10-30重量份、藤梨根20-60重量份。
3.根据权利要求1所述的中药组合物,其特征在于,所述中药组合物的剂型为油膏剂。
4.根据权利要求2所述的中药组合物,其特征在于,所述中药组合物的剂型为颗粒剂或胶囊剂。
5.权利要求3所述治疗消化道肿瘤引发贫血的中药组合物的制备方法,其特征在于,所述油膏剂的制备方法具体如下:
按照所述重量份阿胶进行烊化,得到烊化阿胶;取所述重量份白芨洗净、干燥,之后和血余炭分别进行粉碎,得到白芨粉和血余炭粉;将所述烊化阿胶、白芨粉和血余炭粉混合均匀,得到混合物;向所述混合物中加入鸡蛋油并搅拌均匀,得到所述油膏剂。
6.根据权利要求5所述的制备方法,其特征在于,所述烊化为:将阿胶粉碎,加入为阿胶质量1-2倍的温水,放入蒸锅,隔水蒸之,直到融化,得到所述烊化阿胶。
7.根据权利要求5所述的制备方法,其特征在于,所述白芨粉和血余炭粉的粒径为200目,所述鸡蛋油的加入量为所述混合物的1%-5%。
8.权利要求4所述治疗消化道肿瘤引发贫血的中药组合物的制备方法,其特征在于,所述颗粒剂的制备方法具体如下:
(1)按照所述重量份阿胶进行烊化,得到烊化阿胶;
(2)将剩余所述各原料依次进行清洗、干燥、粉碎、混合,得到原料混合粉,向所述原料混合粉中加水进行第一次煎煮,过滤后得到第一滤渣和第一滤液;向所述第一滤渣中加水进行第二次煎煮,过滤后得到第二滤渣和第二滤液;向所述第二滤渣中加水进行第三次煎煮,过滤后得到第三滤渣和第三滤液;将所述各原料第一滤液、第二滤液、第三滤液和步骤(1)中的烊化阿胶混合均匀,得到合并液;将所述合并液依次进行浓缩、干燥、粉碎,得到所述颗粒剂。
9.根据权利要求8所述的制备方法,其特征在于,步骤(1)中,所述烊化为:将阿胶粉碎,加入为阿胶质量1-2倍的温水,放入蒸锅,隔水蒸之,直到融化,得到所述烊化阿胶。
10.根据权利要求8所述的制备方法,其特征在于,步骤(2)中,所述原料混合粉的粒径为50-100目;所述三次加水的量均为所述原料混合粉质量的4-6倍,所述第一次煎煮的时间为80-100min,所述第二次煎煮的时间为50-70min,所述第三次煎煮的时间为30-50min。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010387030.8A CN111544522A (zh) | 2020-05-09 | 2020-05-09 | 一种治疗消化道肿瘤引发贫血的中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010387030.8A CN111544522A (zh) | 2020-05-09 | 2020-05-09 | 一种治疗消化道肿瘤引发贫血的中药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111544522A true CN111544522A (zh) | 2020-08-18 |
Family
ID=71996428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010387030.8A Pending CN111544522A (zh) | 2020-05-09 | 2020-05-09 | 一种治疗消化道肿瘤引发贫血的中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111544522A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112870294A (zh) * | 2021-03-01 | 2021-06-01 | 天津冠勤医药科技有限公司 | 一种用于抗肿瘤的组合物 |
-
2020
- 2020-05-09 CN CN202010387030.8A patent/CN111544522A/zh active Pending
Non-Patent Citations (4)
Title |
---|
乔小燕等: ""圣愈汤治疗恶性肿瘤化疗后贫血的临床观察"", 《光明中医》 * |
刘长江: "《实用中医小方》", 31 July 2017, 中医古籍出版社 * |
孟建华等: "《胃病千金方》", 30 September 2011, 河北科学技术出版社 * |
费立升等: "《中医辨证施治疑难杂症》", 31 August 2006, 科学技术文献出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112870294A (zh) * | 2021-03-01 | 2021-06-01 | 天津冠勤医药科技有限公司 | 一种用于抗肿瘤的组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103041312B (zh) | 具有抗肿瘤作用的中药组合物及其制备方法和应用 | |
CN103041317B (zh) | 一种治疗肿瘤的中药组合物及其制备方法 | |
CN103768398B (zh) | 一种治疗晚期肺肿瘤的中药组合物 | |
CN105362340B (zh) | 一种治疗白血病的药物组合物及其制备方法 | |
CN111544522A (zh) | 一种治疗消化道肿瘤引发贫血的中药组合物及其制备方法 | |
CN115282229B (zh) | 一种治疗气虚血淤型冠心病的中药组合物及其制备方法 | |
CN105456428A (zh) | 一种抑制肿瘤细胞再生长的中药配方及其制备方法 | |
CN101816745B (zh) | 适用于治疗肝硬化腹水的中药组合物及其制备方法 | |
CN103071039A (zh) | 一种治疗再生障碍性贫血的药物及制备方法 | |
CN108186921B (zh) | 一种抗肿瘤的含硒中药组合物及其制备方法 | |
CN103330827B (zh) | 用于治疗放疗引起的白细胞减少的中药组合物 | |
CN107519261A (zh) | 一种治疗白血病的中药组合物及其制备方法 | |
CN105396019A (zh) | 一种缓解肿瘤病人放疗反应的药物组合物 | |
CN103735745A (zh) | 一种治疗肺部肿瘤的中药制剂及制备方法 | |
CN115531488B (zh) | 一种疏肝健脾、用于乳腺癌术后辅助治疗的组合物及其制备方法 | |
CN108498575B (zh) | 一种治疗食管鳞癌的药物及其制备方法 | |
CN101224295A (zh) | 一种治疗消化系统肿瘤的中药组合物及其制备方法 | |
CN104306539A (zh) | 四物方中药饮片组合制剂、制备方法及组合包装 | |
CN106389871A (zh) | 包括活性紫杉的防癌复方中药组合物及其制备方法 | |
CN1050515C (zh) | 一种治疗白血病的中药组合物及其制法 | |
CN105012789A (zh) | 治疗宫颈癌的组合物及其制备方法 | |
CN105012642A (zh) | 一种活血化瘀,止血止痛的中药组合物的制备方法 | |
WO2023103126A1 (zh) | 一种具有抗癌作用的中药组合物及其制备方法 | |
CN104998019A (zh) | 一种活血化瘀,止血止痛的中药组合物 | |
CN113786451A (zh) | 一种用于治疗妇科肿瘤的中药组合物及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200818 |
|
RJ01 | Rejection of invention patent application after publication |